AXL Receptor Tyrosine Kinase: Emerging Therapeutic Target in Cancer Therapy – Empowered by ANT BIO PTE. LTD.

1. Concept

AXL, a key member of the TAM receptor tyrosine kinase (RTK) family (alongside TYRO3 and MERTK), is a type I transmembrane protein (104 kDa) first identified as an oncogene in 1988. The human AXL gene is localized to chromosome 19q13.2 and consists of 20 exons, encoding a structure with an extracellular domain (signal peptide, two immunoglobulin-like [Ig] domains, two fibronectin type III [FNIII] domains), a transmembrane domain, and an intracellular tyrosine kinase domain. AXL is broadly expressed in epithelial, mesenchymal, and hematopoietic cells, with frequent overexpression in diverse malignancies. Its activation—mediated by ligand-dependent (Gas6 binding) or ligand-independent mechanisms—triggers downstream signaling cascades (e.g., PI3K/Akt, MAPK/ERK) that promote tumor cell growth, metastasis, and drug resistance, establishing it as a promising therapeutic target for overcoming limitations of existing RTK-targeted therapies.

2. Research Frontiers

Recent advances in AXL research have deepened our understanding of its oncogenic role and expanded its translational potential, with key frontiers focusing on mechanism innovation, therapeutic development, and resistance management:

• Activation Mechanism Diversification: Beyond canonical Gas6-dependent dimerization, research has uncovered multiple alternative activation pathways, including Gas6-independent dimerization, heterodimerization with TAM family members (TYRO3/MERTK) or non-TAM RTKs (c-MET, EGFR), transcellular homophilic binding, and fusion genes (e.g., AXL-MBIP in lung adenocarcinoma). These findings highlight the complexity of AXL signaling and inform targeted therapy design.
• Tumor Immune Microenvironment Regulation: Emerging studies explore AXL’s role in modulating the tumor immune microenvironment, including its impact on immune cell infiltration, polarization of tumor-associated macrophages, and immune checkpoint expression. This opens new avenues for combining AXL inhibitors with immunotherapies (e.g., PD-1/PD-L1 blockers) to enhance anti-tumor efficacy.
• Therapeutic Agent Development: AXL-targeted therapies are advancing rapidly, including small molecule inhibitors, monoclonal antibodies, antibody-drug conjugates (ADCs), and bispecific antibodies. Preclinical and clinical studies are evaluating these agents as monotherapies or in combination with existing RTK inhibitors to overcome acquired resistance.
• Resistance Mechanism Exploration: Primary and acquired resistance to AXL inhibitors is a critical challenge. Research is investigating mechanisms such as alternative signaling pathway activation, AXL protein stabilization (impaired ubiquitin-dependent degradation), and epigenetic regulation, with strategies to reverse resistance under preclinical evaluation.
• Biomarker Identification: Efforts are underway to identify predictive biomarkers for AXL-targeted therapy response, including AXL expression levels, Gas6 concentrations, and co-expression of other RTKs (e.g., c-MET, EGFR). These biomarkers aim to improve patient stratification and personalized treatment selection.

3. Research Significance

AXL research holds profound significance for addressing the unmet clinical need of acquired resistance to conventional RTK-targeted therapies. As a key driver of tumor progression and resistance, AXL offers a novel target to inhibit cancer cell survival and metastasis, particularly in malignancies refractory to EGFR, c-MET, or VEGFR inhibitors.

From a biological perspective, studying AXL’s diverse activation mechanisms and signaling networks enhances our understanding of RTK biology and tumorigenesis. Its role in integrating multiple signaling pathways (PI3K/Akt, MAPK/ERK) reveals how tumors exploit redundant signaling to escape therapy, providing insights into broader oncogenic mechanisms.

Translational research on AXL has accelerated the development of novel therapeutic agents, offering new hope for patients with advanced or refractory cancers. For the scientific community, AXL serves as a model for exploring the TAM receptor family and RTK crosstalk, informing research on other understudied RTKs. Additionally, the development of high-quality AXL-specific reagents supports basic research and clinical translation, enabling the validation of AXL’s role in various malignancies.

4. Related Mechanisms, Research Methods, and Product Applications

Core Mechanisms

• AXL Activation Pathways:
• Ligand-Dependent Activation: Binding of Gas6 (growth arrest-specific 6) to AXL induces 1:1 stoichiometric complex formation and receptor dimerization, activating intracellular tyrosine kinase activity.
• Ligand-Independent Activation: Mechanisms include spontaneous dimerization, heterodimerization with other RTKs, oxidative stress-induced activation, and fusion gene formation (e.g., AXL-MBIP).
• Downstream Signaling: Activated AXL phosphorylates downstream substrates, triggering PI3K/Akt (promotes cell survival and proliferation) and MAPK/ERK (enhances cell migration and metastasis) signaling cascades. Additional pathways, such as JAK/STAT and NF-κB, may also be involved in tumor progression.
• Regulatory Mechanisms: AXL expression and function are regulated by epigenetic modifications (promoter methylation), transcription factors (HIF-α, AP-1, YAP1/TEAD), miRNAs, and post-translational modifications (glycosylation, phosphorylation, ubiquitination, proteolytic cleavage).

Research Methods

• Expression Analysis: Techniques such as Western blotting, quantitative PCR (qPCR), immunohistochemistry (IHC), and flow cytometry detect AXL mRNA and protein expression in tumor tissues and cell lines.
• Functional Assays: In vitro assays (cell proliferation, migration, invasion, and apoptosis assays) evaluate the impact of AXL activation or inhibition on cancer cell behavior. In vivo xenograft models assess the anti-tumor efficacy of AXL-targeted agents.
• Signaling Pathway Studies: Immunoprecipitation, Western blotting, and reporter gene assays dissect AXL-mediated downstream signaling cascades and protein-protein interactions.
• Activation Mechanism Validation: Co-immunoprecipitation, surface plasmon resonance (SPR), and gene silencing (siRNA/shRNA) confirm AXL dimerization (homophilic/heterophilic) and ligand-receptor interactions.
• Clinical Sample Analysis: Retrospective and prospective studies correlate AXL expression with patient prognosis and treatment response to validate its clinical utility as a biomarker.

Product Applications by ANT BIO PTE. LTD.

ANT BIO PTE. LTD. provides a comprehensive portfolio of research tools through its specialized sub-brands to support AXL-focused studies and therapeutic development:

• UA Brand (Recombinant Proteins): Supplies high-purity recombinant AXL proteins from multiple species (human, mouse) with various tags (His, Fc, Biotin-Avi), including UA010237 (Human AXL His Tag), UA010672 (Biotinylated Human AXL Fc&Avi Tag), and UA080267 (Human AXL Protein expressed in Baculovirus-Insect Cells). These proteins are critical for ligand-binding studies, antibody screening, and functional assays evaluating AXL activation and signaling.
• STARTER Brand (Antibodies): Offers specific anti-AXL monoclonal antibodies optimized for Western blotting, IHC, and flow cytometry, enabling precise detection and quantification of AXL in tissues and cells. These antibodies support expression analysis and mechanism research.
• Absin Brand (Kits & General Reagents): Provides ELISA kits for quantifying Gas6 (AXL ligand) and downstream signaling molecules (e.g., phosphorylated Akt, ERK), as well as general reagents for cell culture, protein extraction, and immunoprecipitation—streamlining experimental workflows for AXL research.

5. Brand Mission

At ANT BIO PTE. LTD., our mission is to empower global life science researchers, oncologists, and translational scientists by delivering high-quality, reliable reagents and tools that accelerate breakthroughs in cancer therapy and RTK biology. We are committed to supporting the exploration of pivotal targets like AXL through our specialized sub-brands: STARTER (high-specificity antibodies), UA (high-purity recombinant proteins), and Absin (reliable kits & general reagents). Leveraging advanced development platforms—including recombinant rabbit/mouse monoclonal antibody technology, multi-system protein expression (E.coli, CHO, HEK293, Insect Cells), and One-Step ELISA platforms—we adhere to rigorous quality standards (compliant with EU 98/79/EC, ISO9001, and ISO13485 certifications) to ensure product consistency, specificity, and performance. Our dedication to innovation, quality, and customer-centricity drives us to contribute to advancements in cancer diagnosis, treatment, and personalized medicine, ultimately improving the lives of patients with advanced malignancies.

6. Related Product List

7. AI Disclaimer

This article is AI-compiled and interpreted based on the original work. All intellectual property (e.g., images, data) of the original publication shall belong to the journal and the research team. For any infringement, please contact us promptly and we will take immediate action.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.